Ozmosi | Gosogliptin Drug Profile
Drug Profile
Using advanced filters...

Gosogliptin

Alternative Names: gosogliptin, pf-00734200
Clinical Status: Inactive
Latest Update: 2017-03-23
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DPP4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Russia

Approved Indications: None

Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Type 2 Diabetes

Phase 1: Kidney Failure, Chronic

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT00596518

A7941014

P1

Completed

Kidney Failure, Chronic

2008-07-01

2019-03-22

Treatments

2007-007588-26

2007-007588-26

P2

Completed

Type 2 Diabetes

2008-08-26

2022-03-12

Treatments

NCT00618007

A7941006

P2

Completed

Type 2 Diabetes

2008-08-01

2019-03-18

Treatments

2007-001922-28

2007-001922-28

P2

Completed

Type 2 Diabetes

2008-06-26

2025-07-05

Treatments

NCT00473525

A7941005

P2

Completed

Type 2 Diabetes

2008-06-01

2019-03-21

Treatments

NCT03088670

SRX-1374-02

P3

Completed

Type 2 Diabetes

2014-03-30

2019-03-21

Treatments

Recent News Events

Date

Type

Title